Clinical Trial Search

Primary: Analgesic Efficacy From 0 to 6 Hours After the Dose Using the Time-weighted Sum of Pain Intensity Difference (SPID 0-6) — 4.37; 20.75; 8.95; 20.56 units on a scale…

Primary: The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set (Co-primary Analyses) — 245; 270; 79; 70…

Primary: Percentage of Heavy Drinking Days at Week 16 Endpoint — -43.02; -38.72 percentage of days — p=0.120

Primary: Mean Error (ME) +/- 1 Breath Per Minute, RR Sensor — -0.82 BrPM (breaths per minute)

Primary: Trough (AM Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) at the End of the 6-week Treatment Period — 2.36; 2.39; 2.40; 2.42 Liters…

Primary: Gastric Emptying Time — 105; 180 minutes — p=0.036

Primary: Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants — 0; 0; 1 participants

Primary: Weight Changes in Veterans With MetS. — -2.3; -6.2 kg

Primary: The Efficacy of the Triage Neutraphil-Gelatinase Associated Lipocalin (NGAL) Test as an Aid in the Diagnosis of Acute Kidney Injury (AKI) in an All-comers ICU Setting…

Primary: The Percentage of Subjects Who Achieve 12-week Sustained Virologic Response (SVR12) — 90 percentage of participants

Primary: Progression Free Survival (PFS) — 4.3; 2.6 months — p=0.0006

Primary: Brain Atrophy by MRI — -0.4; -1.3 whole brain percent volume change

Primary: Brachial Artery Diameter Change From Baseline in Response to Reactive Hyperemia — 8.3; 9.43 % changes in diameter of artery

Primary: Diagnosis Rate of Asthma — 54; 87 Participants

Primary: Percentage of Participants With Overall Response — 11.1; 29.2 percentage of participants